nodes	percent_of_prediction	percent_of_DWPC	metapath
Dalfampridine—KCNH1—embryo—testicular cancer	0.0384	0.0623	CbGeAlD
Dalfampridine—KCNG2—testis—testicular cancer	0.0292	0.0473	CbGeAlD
Dalfampridine—KCND1—embryo—testicular cancer	0.0285	0.0462	CbGeAlD
Dalfampridine—KCNS1—seminal vesicle—testicular cancer	0.028	0.0454	CbGeAlD
Dalfampridine—KCNF1—seminal vesicle—testicular cancer	0.0229	0.0372	CbGeAlD
Dalfampridine—KCNS3—seminal vesicle—testicular cancer	0.0201	0.0326	CbGeAlD
Dalfampridine—KCNV2—testis—testicular cancer	0.0197	0.032	CbGeAlD
Dalfampridine—KCND1—gonad—testicular cancer	0.0193	0.0314	CbGeAlD
Dalfampridine—KCNH1—testis—testicular cancer	0.0188	0.0305	CbGeAlD
Dalfampridine—KCNH3—testis—testicular cancer	0.0167	0.0272	CbGeAlD
Dalfampridine—KCNG1—testis—testicular cancer	0.0167	0.0272	CbGeAlD
Dalfampridine—KCNH8—testis—testicular cancer	0.0162	0.0263	CbGeAlD
Dalfampridine—KCNC3—testis—testicular cancer	0.0157	0.0256	CbGeAlD
Dalfampridine—KCNA5—gonad—testicular cancer	0.0148	0.024	CbGeAlD
Dalfampridine—KCNQ1—seminal vesicle—testicular cancer	0.0148	0.024	CbGeAlD
Dalfampridine—KCNA2—testis—testicular cancer	0.0146	0.0236	CbGeAlD
Dalfampridine—KCNS1—testis—testicular cancer	0.0146	0.0236	CbGeAlD
Dalfampridine—KCND1—testis—testicular cancer	0.0139	0.0226	CbGeAlD
Dalfampridine—KCNC4—testis—testicular cancer	0.0139	0.0226	CbGeAlD
Dalfampridine—KCNH7—testis—testicular cancer	0.0134	0.0217	CbGeAlD
Dalfampridine—KCNC1—testis—testicular cancer	0.0134	0.0217	CbGeAlD
Dalfampridine—KCNQ4—testis—testicular cancer	0.0134	0.0217	CbGeAlD
Dalfampridine—KCNQ2—gonad—testicular cancer	0.0133	0.0217	CbGeAlD
Dalfampridine—KCNA5—female gonad—testicular cancer	0.012	0.0195	CbGeAlD
Dalfampridine—KCNA3—lymph node—testicular cancer	0.0111	0.018	CbGeAlD
Dalfampridine—KCNQ2—female gonad—testicular cancer	0.0108	0.0176	CbGeAlD
Dalfampridine—KCNA5—testis—testicular cancer	0.0107	0.0173	CbGeAlD
Dalfampridine—KCNA2—lymph node—testicular cancer	0.0106	0.0171	CbGeAlD
Dalfampridine—KCNS3—testis—testicular cancer	0.0104	0.017	CbGeAlD
Dalfampridine—KCND2—female gonad—testicular cancer	0.0103	0.0167	CbGeAlD
Dalfampridine—KCNC4—lymph node—testicular cancer	0.0101	0.0164	CbGeAlD
Dalfampridine—KCNQ2—testis—testicular cancer	0.00962	0.0156	CbGeAlD
Dalfampridine—KCNQ5—lymph node—testicular cancer	0.00944	0.0153	CbGeAlD
Dalfampridine—KCND2—testis—testicular cancer	0.00911	0.0148	CbGeAlD
Dalfampridine—KCNQ1—female gonad—testicular cancer	0.00867	0.0141	CbGeAlD
Dalfampridine—KCND3—testis—testicular cancer	0.00794	0.0129	CbGeAlD
Dalfampridine—KCNA5—lymph node—testicular cancer	0.00774	0.0126	CbGeAlD
Dalfampridine—KCNQ1—testis—testicular cancer	0.00769	0.0125	CbGeAlD
Dalfampridine—KCNS3—lymph node—testicular cancer	0.00757	0.0123	CbGeAlD
Dalfampridine—Infection—Carboplatin—testicular cancer	0.00668	0.0174	CcSEcCtD
Dalfampridine—KCND3—lymph node—testicular cancer	0.00576	0.00934	CbGeAlD
Dalfampridine—Chest discomfort—Etoposide—testicular cancer	0.00572	0.0149	CcSEcCtD
Dalfampridine—KCNH2—seminal vesicle—testicular cancer	0.00563	0.00914	CbGeAlD
Dalfampridine—KCNQ1—lymph node—testicular cancer	0.00557	0.00905	CbGeAlD
Dalfampridine—CYP2E1—seminal vesicle—testicular cancer	0.00433	0.00704	CbGeAlD
Dalfampridine—Tremor—Chlorambucil—testicular cancer	0.00397	0.0103	CcSEcCtD
Dalfampridine—Angioedema—Chlorambucil—testicular cancer	0.00387	0.0101	CcSEcCtD
Dalfampridine—Convulsion—Chlorambucil—testicular cancer	0.00367	0.00956	CcSEcCtD
Dalfampridine—Nasopharyngitis—Cisplatin—testicular cancer	0.00359	0.00935	CcSEcCtD
Dalfampridine—Infestation—Ifosfamide—testicular cancer	0.00359	0.00934	CcSEcCtD
Dalfampridine—Infestation NOS—Ifosfamide—testicular cancer	0.00359	0.00934	CcSEcCtD
Dalfampridine—Confusional state—Chlorambucil—testicular cancer	0.00349	0.00908	CcSEcCtD
Dalfampridine—Infection—Chlorambucil—testicular cancer	0.00344	0.00895	CcSEcCtD
Dalfampridine—Convulsion—Vinblastine—testicular cancer	0.00337	0.00876	CcSEcCtD
Dalfampridine—KCNH2—female gonad—testicular cancer	0.0033	0.00537	CbGeAlD
Dalfampridine—Connective tissue disorder—Ifosfamide—testicular cancer	0.00317	0.00824	CcSEcCtD
Dalfampridine—Dyspepsia—Chlorambucil—testicular cancer	0.00305	0.00793	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.00299	0.00778	CcSEcCtD
Dalfampridine—KCNH2—testis—testicular cancer	0.00293	0.00476	CbGeAlD
Dalfampridine—Angiopathy—Ifosfamide—testicular cancer	0.00292	0.00761	CcSEcCtD
Dalfampridine—Immune system disorder—Ifosfamide—testicular cancer	0.00291	0.00757	CcSEcCtD
Dalfampridine—Mediastinal disorder—Ifosfamide—testicular cancer	0.0029	0.00756	CcSEcCtD
Dalfampridine—Feeling abnormal—Chlorambucil—testicular cancer	0.00285	0.00742	CcSEcCtD
Dalfampridine—Paraesthesia—Vinblastine—testicular cancer	0.00285	0.00741	CcSEcCtD
Dalfampridine—Infestation NOS—Etoposide—testicular cancer	0.00283	0.00738	CcSEcCtD
Dalfampridine—Infestation—Etoposide—testicular cancer	0.00283	0.00738	CcSEcCtD
Dalfampridine—Mental disorder—Ifosfamide—testicular cancer	0.00282	0.00735	CcSEcCtD
Dalfampridine—Chest pain—Bleomycin—testicular cancer	0.00279	0.00727	CcSEcCtD
Dalfampridine—Urticaria—Chlorambucil—testicular cancer	0.00275	0.00716	CcSEcCtD
Dalfampridine—Connective tissue disorder—Cisplatin—testicular cancer	0.00273	0.0071	CcSEcCtD
Dalfampridine—Constipation—Vinblastine—testicular cancer	0.00271	0.00706	CcSEcCtD
Dalfampridine—Confusional state—Bleomycin—testicular cancer	0.0027	0.00703	CcSEcCtD
Dalfampridine—Anaphylactic shock—Bleomycin—testicular cancer	0.00268	0.00697	CcSEcCtD
Dalfampridine—Infection—Bleomycin—testicular cancer	0.00266	0.00693	CcSEcCtD
Dalfampridine—Feeling abnormal—Vinblastine—testicular cancer	0.00261	0.0068	CcSEcCtD
Dalfampridine—Angioedema—Ifosfamide—testicular cancer	0.00256	0.00667	CcSEcCtD
Dalfampridine—Hypersensitivity—Chlorambucil—testicular cancer	0.00255	0.00664	CcSEcCtD
Dalfampridine—Immune system disorder—Cisplatin—testicular cancer	0.00251	0.00653	CcSEcCtD
Dalfampridine—Mediastinal disorder—Cisplatin—testicular cancer	0.0025	0.00652	CcSEcCtD
Dalfampridine—Hypotension—Bleomycin—testicular cancer	0.0025	0.00651	CcSEcCtD
Dalfampridine—Asthenia—Chlorambucil—testicular cancer	0.00248	0.00646	CcSEcCtD
Dalfampridine—Infection—Dactinomycin—testicular cancer	0.00248	0.00646	CcSEcCtD
Dalfampridine—Convulsion—Ifosfamide—testicular cancer	0.00243	0.00633	CcSEcCtD
Dalfampridine—Paraesthesia—Bleomycin—testicular cancer	0.0024	0.00626	CcSEcCtD
Dalfampridine—Dyspnoea—Bleomycin—testicular cancer	0.00239	0.00622	CcSEcCtD
Dalfampridine—Chest pain—Ifosfamide—testicular cancer	0.00239	0.00622	CcSEcCtD
Dalfampridine—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.00237	0.00617	CcSEcCtD
Dalfampridine—Hypersensitivity—Vinblastine—testicular cancer	0.00234	0.00608	CcSEcCtD
Dalfampridine—Angiopathy—Etoposide—testicular cancer	0.00231	0.00601	CcSEcCtD
Dalfampridine—Confusional state—Ifosfamide—testicular cancer	0.00231	0.00601	CcSEcCtD
Dalfampridine—Immune system disorder—Etoposide—testicular cancer	0.0023	0.00598	CcSEcCtD
Dalfampridine—Mediastinal disorder—Etoposide—testicular cancer	0.00229	0.00597	CcSEcCtD
Dalfampridine—Anaphylactic shock—Ifosfamide—testicular cancer	0.00229	0.00596	CcSEcCtD
Dalfampridine—Asthenia—Vinblastine—testicular cancer	0.00227	0.00592	CcSEcCtD
Dalfampridine—Infection—Ifosfamide—testicular cancer	0.00227	0.00592	CcSEcCtD
Dalfampridine—Tremor—Cisplatin—testicular cancer	0.00226	0.0059	CcSEcCtD
Dalfampridine—CYP2E1—testis—testicular cancer	0.00226	0.00366	CbGeAlD
Dalfampridine—Nervous system disorder—Ifosfamide—testicular cancer	0.00224	0.00584	CcSEcCtD
Dalfampridine—Skin disorder—Ifosfamide—testicular cancer	0.00222	0.00579	CcSEcCtD
Dalfampridine—Feeling abnormal—Bleomycin—testicular cancer	0.00221	0.00574	CcSEcCtD
Dalfampridine—Vomiting—Chlorambucil—testicular cancer	0.0022	0.00573	CcSEcCtD
Dalfampridine—Back pain—Etoposide—testicular cancer	0.00214	0.00558	CcSEcCtD
Dalfampridine—Hypotension—Ifosfamide—testicular cancer	0.00214	0.00557	CcSEcCtD
Dalfampridine—Urticaria—Bleomycin—testicular cancer	0.00213	0.00554	CcSEcCtD
Dalfampridine—KCNH2—lymph node—testicular cancer	0.00212	0.00345	CbGeAlD
Dalfampridine—Dizziness—Vinblastine—testicular cancer	0.0021	0.00546	CcSEcCtD
Dalfampridine—Convulsion—Cisplatin—testicular cancer	0.00209	0.00545	CcSEcCtD
Dalfampridine—Feeling abnormal—Dactinomycin—testicular cancer	0.00206	0.00536	CcSEcCtD
Dalfampridine—Nausea—Chlorambucil—testicular cancer	0.00205	0.00535	CcSEcCtD
Dalfampridine—Paraesthesia—Ifosfamide—testicular cancer	0.00205	0.00535	CcSEcCtD
Dalfampridine—Anxiety—Cisplatin—testicular cancer	0.00205	0.00534	CcSEcCtD
Dalfampridine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.00204	0.00532	CcSEcCtD
Dalfampridine—Dyspnoea—Ifosfamide—testicular cancer	0.00204	0.00531	CcSEcCtD
Dalfampridine—Vomiting—Vinblastine—testicular cancer	0.00202	0.00525	CcSEcCtD
Dalfampridine—Headache—Vinblastine—testicular cancer	0.00199	0.00517	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00198	0.00514	CcSEcCtD
Dalfampridine—Anaphylactic shock—Cisplatin—testicular cancer	0.00197	0.00514	CcSEcCtD
Dalfampridine—Hypersensitivity—Bleomycin—testicular cancer	0.00197	0.00514	CcSEcCtD
Dalfampridine—Infection—Cisplatin—testicular cancer	0.00196	0.0051	CcSEcCtD
Dalfampridine—Constipation—Ifosfamide—testicular cancer	0.00196	0.00509	CcSEcCtD
Dalfampridine—Nervous system disorder—Cisplatin—testicular cancer	0.00193	0.00504	CcSEcCtD
Dalfampridine—Asthenia—Bleomycin—testicular cancer	0.00192	0.005	CcSEcCtD
Dalfampridine—Convulsion—Etoposide—testicular cancer	0.00192	0.005	CcSEcCtD
Dalfampridine—Skin disorder—Cisplatin—testicular cancer	0.00192	0.00499	CcSEcCtD
Dalfampridine—Feeling abnormal—Ifosfamide—testicular cancer	0.00189	0.00491	CcSEcCtD
Dalfampridine—Chest pain—Etoposide—testicular cancer	0.00189	0.00491	CcSEcCtD
Dalfampridine—Nausea—Vinblastine—testicular cancer	0.00188	0.0049	CcSEcCtD
Dalfampridine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.00187	0.00487	CcSEcCtD
Dalfampridine—Hypotension—Cisplatin—testicular cancer	0.00184	0.0048	CcSEcCtD
Dalfampridine—Nasopharyngitis—Epirubicin—testicular cancer	0.00184	0.0048	CcSEcCtD
Dalfampridine—Hypersensitivity—Dactinomycin—testicular cancer	0.00184	0.00479	CcSEcCtD
Dalfampridine—Confusional state—Etoposide—testicular cancer	0.00182	0.00474	CcSEcCtD
Dalfampridine—Urticaria—Ifosfamide—testicular cancer	0.00182	0.00473	CcSEcCtD
Dalfampridine—Anaphylactic shock—Etoposide—testicular cancer	0.00181	0.00471	CcSEcCtD
Dalfampridine—Infection—Etoposide—testicular cancer	0.0018	0.00467	CcSEcCtD
Dalfampridine—Asthenia—Dactinomycin—testicular cancer	0.00179	0.00466	CcSEcCtD
Dalfampridine—Paraesthesia—Cisplatin—testicular cancer	0.00177	0.00461	CcSEcCtD
Dalfampridine—Dyspnoea—Cisplatin—testicular cancer	0.00176	0.00458	CcSEcCtD
Dalfampridine—Skin disorder—Etoposide—testicular cancer	0.00176	0.00457	CcSEcCtD
Dalfampridine—Nasopharyngitis—Doxorubicin—testicular cancer	0.00171	0.00444	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Cisplatin—testicular cancer	0.0017	0.00443	CcSEcCtD
Dalfampridine—Vomiting—Bleomycin—testicular cancer	0.0017	0.00443	CcSEcCtD
Dalfampridine—Infestation NOS—Methotrexate—testicular cancer	0.0017	0.00442	CcSEcCtD
Dalfampridine—Infestation—Methotrexate—testicular cancer	0.0017	0.00442	CcSEcCtD
Dalfampridine—Hypotension—Etoposide—testicular cancer	0.00169	0.0044	CcSEcCtD
Dalfampridine—Rash—Bleomycin—testicular cancer	0.00169	0.0044	CcSEcCtD
Dalfampridine—Dermatitis—Bleomycin—testicular cancer	0.00169	0.00439	CcSEcCtD
Dalfampridine—Hypersensitivity—Ifosfamide—testicular cancer	0.00169	0.00439	CcSEcCtD
Dalfampridine—Asthenia—Ifosfamide—testicular cancer	0.00164	0.00427	CcSEcCtD
Dalfampridine—Feeling abnormal—Cisplatin—testicular cancer	0.00163	0.00423	CcSEcCtD
Dalfampridine—Paraesthesia—Etoposide—testicular cancer	0.00162	0.00423	CcSEcCtD
Dalfampridine—Dyspnoea—Etoposide—testicular cancer	0.00161	0.0042	CcSEcCtD
Dalfampridine—Nausea—Bleomycin—testicular cancer	0.00159	0.00414	CcSEcCtD
Dalfampridine—Infestation NOS—Epirubicin—testicular cancer	0.00159	0.00414	CcSEcCtD
Dalfampridine—Infestation—Epirubicin—testicular cancer	0.00159	0.00414	CcSEcCtD
Dalfampridine—Vomiting—Dactinomycin—testicular cancer	0.00159	0.00413	CcSEcCtD
Dalfampridine—Rash—Dactinomycin—testicular cancer	0.00157	0.0041	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Etoposide—testicular cancer	0.00156	0.00406	CcSEcCtD
Dalfampridine—Constipation—Etoposide—testicular cancer	0.00155	0.00402	CcSEcCtD
Dalfampridine—Urinary tract infection—Epirubicin—testicular cancer	0.00154	0.00402	CcSEcCtD
Dalfampridine—Dizziness—Ifosfamide—testicular cancer	0.00151	0.00394	CcSEcCtD
Dalfampridine—Feeling abnormal—Etoposide—testicular cancer	0.00149	0.00388	CcSEcCtD
Dalfampridine—Nausea—Dactinomycin—testicular cancer	0.00148	0.00386	CcSEcCtD
Dalfampridine—Infestation NOS—Doxorubicin—testicular cancer	0.00147	0.00383	CcSEcCtD
Dalfampridine—Infestation—Doxorubicin—testicular cancer	0.00147	0.00383	CcSEcCtD
Dalfampridine—Vomiting—Ifosfamide—testicular cancer	0.00145	0.00379	CcSEcCtD
Dalfampridine—Hypersensitivity—Cisplatin—testicular cancer	0.00145	0.00378	CcSEcCtD
Dalfampridine—Rash—Ifosfamide—testicular cancer	0.00144	0.00376	CcSEcCtD
Dalfampridine—Dermatitis—Ifosfamide—testicular cancer	0.00144	0.00375	CcSEcCtD
Dalfampridine—Urticaria—Etoposide—testicular cancer	0.00144	0.00374	CcSEcCtD
Dalfampridine—Urinary tract infection—Doxorubicin—testicular cancer	0.00143	0.00372	CcSEcCtD
Dalfampridine—Asthenia—Cisplatin—testicular cancer	0.00142	0.00369	CcSEcCtD
Dalfampridine—Connective tissue disorder—Epirubicin—testicular cancer	0.0014	0.00365	CcSEcCtD
Dalfampridine—Angiopathy—Methotrexate—testicular cancer	0.00138	0.0036	CcSEcCtD
Dalfampridine—Immune system disorder—Methotrexate—testicular cancer	0.00138	0.00358	CcSEcCtD
Dalfampridine—Mediastinal disorder—Methotrexate—testicular cancer	0.00137	0.00358	CcSEcCtD
Dalfampridine—Nausea—Ifosfamide—testicular cancer	0.00136	0.00354	CcSEcCtD
Dalfampridine—Mental disorder—Methotrexate—testicular cancer	0.00133	0.00348	CcSEcCtD
Dalfampridine—Hypersensitivity—Etoposide—testicular cancer	0.00133	0.00347	CcSEcCtD
Dalfampridine—Asthenia—Etoposide—testicular cancer	0.0013	0.00338	CcSEcCtD
Dalfampridine—Connective tissue disorder—Doxorubicin—testicular cancer	0.0013	0.00338	CcSEcCtD
Dalfampridine—Angiopathy—Epirubicin—testicular cancer	0.00129	0.00337	CcSEcCtD
Dalfampridine—Immune system disorder—Epirubicin—testicular cancer	0.00129	0.00335	CcSEcCtD
Dalfampridine—Mediastinal disorder—Epirubicin—testicular cancer	0.00129	0.00335	CcSEcCtD
Dalfampridine—Back pain—Methotrexate—testicular cancer	0.00128	0.00334	CcSEcCtD
Dalfampridine—Vomiting—Cisplatin—testicular cancer	0.00125	0.00327	CcSEcCtD
Dalfampridine—Mental disorder—Epirubicin—testicular cancer	0.00125	0.00325	CcSEcCtD
Dalfampridine—Rash—Cisplatin—testicular cancer	0.00124	0.00324	CcSEcCtD
Dalfampridine—Dermatitis—Cisplatin—testicular cancer	0.00124	0.00324	CcSEcCtD
Dalfampridine—Back pain—Epirubicin—testicular cancer	0.0012	0.00313	CcSEcCtD
Dalfampridine—Angiopathy—Doxorubicin—testicular cancer	0.0012	0.00312	CcSEcCtD
Dalfampridine—Dizziness—Etoposide—testicular cancer	0.0012	0.00311	CcSEcCtD
Dalfampridine—Immune system disorder—Doxorubicin—testicular cancer	0.00119	0.0031	CcSEcCtD
Dalfampridine—Mediastinal disorder—Doxorubicin—testicular cancer	0.00119	0.0031	CcSEcCtD
Dalfampridine—Nausea—Cisplatin—testicular cancer	0.00117	0.00305	CcSEcCtD
Dalfampridine—Mental disorder—Doxorubicin—testicular cancer	0.00116	0.00301	CcSEcCtD
Dalfampridine—Convulsion—Methotrexate—testicular cancer	0.00115	0.00299	CcSEcCtD
Dalfampridine—Vomiting—Etoposide—testicular cancer	0.00115	0.00299	CcSEcCtD
Dalfampridine—Rash—Etoposide—testicular cancer	0.00114	0.00297	CcSEcCtD
Dalfampridine—Dermatitis—Etoposide—testicular cancer	0.00114	0.00296	CcSEcCtD
Dalfampridine—Headache—Etoposide—testicular cancer	0.00113	0.00295	CcSEcCtD
Dalfampridine—Chest pain—Methotrexate—testicular cancer	0.00113	0.00294	CcSEcCtD
Dalfampridine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.00112	0.00292	CcSEcCtD
Dalfampridine—Back pain—Doxorubicin—testicular cancer	0.00111	0.00289	CcSEcCtD
Dalfampridine—Confusional state—Methotrexate—testicular cancer	0.00109	0.00284	CcSEcCtD
Dalfampridine—Anaphylactic shock—Methotrexate—testicular cancer	0.00108	0.00282	CcSEcCtD
Dalfampridine—Convulsion—Epirubicin—testicular cancer	0.00108	0.0028	CcSEcCtD
Dalfampridine—Infection—Methotrexate—testicular cancer	0.00108	0.0028	CcSEcCtD
Dalfampridine—Nausea—Etoposide—testicular cancer	0.00107	0.0028	CcSEcCtD
Dalfampridine—Nervous system disorder—Methotrexate—testicular cancer	0.00106	0.00276	CcSEcCtD
Dalfampridine—Chest pain—Epirubicin—testicular cancer	0.00106	0.00275	CcSEcCtD
Dalfampridine—Anxiety—Epirubicin—testicular cancer	0.00105	0.00274	CcSEcCtD
Dalfampridine—Skin disorder—Methotrexate—testicular cancer	0.00105	0.00274	CcSEcCtD
Dalfampridine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.00105	0.00273	CcSEcCtD
Dalfampridine—Confusional state—Epirubicin—testicular cancer	0.00102	0.00266	CcSEcCtD
Dalfampridine—Anaphylactic shock—Epirubicin—testicular cancer	0.00101	0.00264	CcSEcCtD
Dalfampridine—Hypotension—Methotrexate—testicular cancer	0.00101	0.00263	CcSEcCtD
Dalfampridine—Infection—Epirubicin—testicular cancer	0.00101	0.00262	CcSEcCtD
Dalfampridine—Convulsion—Doxorubicin—testicular cancer	0.000995	0.00259	CcSEcCtD
Dalfampridine—Nervous system disorder—Epirubicin—testicular cancer	0.000993	0.00259	CcSEcCtD
Dalfampridine—Skin disorder—Epirubicin—testicular cancer	0.000984	0.00256	CcSEcCtD
Dalfampridine—Insomnia—Methotrexate—testicular cancer	0.000979	0.00255	CcSEcCtD
Dalfampridine—Chest pain—Doxorubicin—testicular cancer	0.000978	0.00255	CcSEcCtD
Dalfampridine—Anxiety—Doxorubicin—testicular cancer	0.000974	0.00254	CcSEcCtD
Dalfampridine—Paraesthesia—Methotrexate—testicular cancer	0.000972	0.00253	CcSEcCtD
Dalfampridine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000971	0.00253	CcSEcCtD
Dalfampridine—Dyspnoea—Methotrexate—testicular cancer	0.000965	0.00251	CcSEcCtD
Dalfampridine—Dyspepsia—Methotrexate—testicular cancer	0.000953	0.00248	CcSEcCtD
Dalfampridine—Hypotension—Epirubicin—testicular cancer	0.000947	0.00246	CcSEcCtD
Dalfampridine—Confusional state—Doxorubicin—testicular cancer	0.000945	0.00246	CcSEcCtD
Dalfampridine—Anaphylactic shock—Doxorubicin—testicular cancer	0.000937	0.00244	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000935	0.00243	CcSEcCtD
Dalfampridine—Infection—Doxorubicin—testicular cancer	0.000931	0.00242	CcSEcCtD
Dalfampridine—Nervous system disorder—Doxorubicin—testicular cancer	0.000919	0.00239	CcSEcCtD
Dalfampridine—Insomnia—Epirubicin—testicular cancer	0.000916	0.00239	CcSEcCtD
Dalfampridine—Skin disorder—Doxorubicin—testicular cancer	0.00091	0.00237	CcSEcCtD
Dalfampridine—Paraesthesia—Epirubicin—testicular cancer	0.00091	0.00237	CcSEcCtD
Dalfampridine—Dyspnoea—Epirubicin—testicular cancer	0.000903	0.00235	CcSEcCtD
Dalfampridine—Feeling abnormal—Methotrexate—testicular cancer	0.000892	0.00232	CcSEcCtD
Dalfampridine—Dyspepsia—Epirubicin—testicular cancer	0.000892	0.00232	CcSEcCtD
Dalfampridine—Hypotension—Doxorubicin—testicular cancer	0.000876	0.00228	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000875	0.00228	CcSEcCtD
Dalfampridine—Constipation—Epirubicin—testicular cancer	0.000866	0.00226	CcSEcCtD
Dalfampridine—Urticaria—Methotrexate—testicular cancer	0.00086	0.00224	CcSEcCtD
Dalfampridine—Insomnia—Doxorubicin—testicular cancer	0.000848	0.00221	CcSEcCtD
Dalfampridine—Paraesthesia—Doxorubicin—testicular cancer	0.000842	0.00219	CcSEcCtD
Dalfampridine—Dyspnoea—Doxorubicin—testicular cancer	0.000836	0.00218	CcSEcCtD
Dalfampridine—Feeling abnormal—Epirubicin—testicular cancer	0.000835	0.00217	CcSEcCtD
Dalfampridine—Dyspepsia—Doxorubicin—testicular cancer	0.000825	0.00215	CcSEcCtD
Dalfampridine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000809	0.00211	CcSEcCtD
Dalfampridine—Urticaria—Epirubicin—testicular cancer	0.000805	0.0021	CcSEcCtD
Dalfampridine—Constipation—Doxorubicin—testicular cancer	0.000802	0.00209	CcSEcCtD
Dalfampridine—Hypersensitivity—Methotrexate—testicular cancer	0.000798	0.00208	CcSEcCtD
Dalfampridine—Asthenia—Methotrexate—testicular cancer	0.000777	0.00202	CcSEcCtD
Dalfampridine—Feeling abnormal—Doxorubicin—testicular cancer	0.000772	0.00201	CcSEcCtD
Dalfampridine—Hypersensitivity—Epirubicin—testicular cancer	0.000746	0.00194	CcSEcCtD
Dalfampridine—Urticaria—Doxorubicin—testicular cancer	0.000745	0.00194	CcSEcCtD
Dalfampridine—Asthenia—Epirubicin—testicular cancer	0.000727	0.00189	CcSEcCtD
Dalfampridine—Dizziness—Methotrexate—testicular cancer	0.000716	0.00186	CcSEcCtD
Dalfampridine—Hypersensitivity—Doxorubicin—testicular cancer	0.000691	0.0018	CcSEcCtD
Dalfampridine—Vomiting—Methotrexate—testicular cancer	0.000688	0.00179	CcSEcCtD
Dalfampridine—Rash—Methotrexate—testicular cancer	0.000683	0.00178	CcSEcCtD
Dalfampridine—Dermatitis—Methotrexate—testicular cancer	0.000682	0.00178	CcSEcCtD
Dalfampridine—Headache—Methotrexate—testicular cancer	0.000678	0.00177	CcSEcCtD
Dalfampridine—Asthenia—Doxorubicin—testicular cancer	0.000673	0.00175	CcSEcCtD
Dalfampridine—Dizziness—Epirubicin—testicular cancer	0.00067	0.00174	CcSEcCtD
Dalfampridine—Vomiting—Epirubicin—testicular cancer	0.000644	0.00168	CcSEcCtD
Dalfampridine—Nausea—Methotrexate—testicular cancer	0.000643	0.00167	CcSEcCtD
Dalfampridine—Rash—Epirubicin—testicular cancer	0.000639	0.00166	CcSEcCtD
Dalfampridine—Dermatitis—Epirubicin—testicular cancer	0.000638	0.00166	CcSEcCtD
Dalfampridine—Headache—Epirubicin—testicular cancer	0.000635	0.00165	CcSEcCtD
Dalfampridine—Dizziness—Doxorubicin—testicular cancer	0.00062	0.00161	CcSEcCtD
Dalfampridine—Nausea—Epirubicin—testicular cancer	0.000602	0.00157	CcSEcCtD
Dalfampridine—Vomiting—Doxorubicin—testicular cancer	0.000596	0.00155	CcSEcCtD
Dalfampridine—Rash—Doxorubicin—testicular cancer	0.000591	0.00154	CcSEcCtD
Dalfampridine—Dermatitis—Doxorubicin—testicular cancer	0.00059	0.00154	CcSEcCtD
Dalfampridine—Headache—Doxorubicin—testicular cancer	0.000587	0.00153	CcSEcCtD
Dalfampridine—Nausea—Doxorubicin—testicular cancer	0.000557	0.00145	CcSEcCtD
